China-originated BeOne reported USD 94 million in Q2 2025 GAAP net income, marking its first profitable quarter, as global sales of BTK inhibitor Brukinsa (zanubrutinib) surged 49% to USD 950 million. The company raised its 2025 revenue forecast to RMB 35.8 to 38.1 billion (USD 5 to 5.3 billion) and expects positive free cash flow for the full year. Brukinsa's US sales grew 43% to USD 684 million, while European revenue reached USD 150 million following expanded reimbursement in five markets. BeOne's gross margin improved to 87.4% as manufacturing efficiencies offset rising SG&A costs.

The company highlighted 20 upcoming clinical milestones, including Phase III readouts for BCL2 inhibitor sonrotoclax in mantle cell lymphoma (MCL) and BTK degrader BGB-16673 in chronic lymphocytic leukemia (CLL). In solid tumours, PRMT5 inhibitor BGB-58067 and HER2 bispecific zanidatamab are advancing, with eight proof-of-concept data readouts expected within 18 months. BeOne’s shares rose 4% in pre-market trading following the earnings release, capping a 52% year-to-date gain on the Shanghai Stock Exchange (SSE).

According to PharmCube's NextBiopharm® database, Brukinsa sales have been growing continuously since the drug's launch in 2019. Click here to request a free trial for NextBiopharm®.